Route 92 Medical, Inc.
$9.7M 774 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
EyePoint Pharmaceuticals US, Inc.
EyePoint Pharmaceuticals US, Inc. reported $9,673,376.83 across General Payments, Research, and Ownership to 748 physicians and teaching hospitals across 902 transactions.
- $9.7M Top 10% payer
- All-tracks total
- 902 Above-median volume
- Transactions
- 748 Above-median reach
- Recipients
- +$331.3K
- General Payments vs PY2023
EyePoint Pharmaceuticals US, Inc. reported $9,673,376.83 across all CMS Open Payments tracks (General + Research + Ownership) to 748 physicians and teaching hospitals in Program Year 2024 - ranking #181 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $827,774.45, averaging $12.9K per recipient.
How EyePoint Pharmaceuticals US, Inc.'s $9.7M all-tracks total breaks down
EyePoint Pharmaceuticals US, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
49/100
Total payments
A
99/100
Transaction volume
F
17/100
Physician reach
F
16/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer eyepoint-pharmaceuticals-us-inc EyePoint Pharmaceuticals US, Inc.
$9.7M · #181/1,925 · 0.1% industry · PY2024
- TOT $9.7M
- RANK #181
- SHARE 0.1%
- TXN 902
- RCP 748
- CAT 5
- GEN $827.8K
- ΔGEN +$331.3K
- TOP1 14.2%
- PY 2024
Volume peers
Nearest volume peer: Route 92 Medical, Inc. ($9.7M)
EyePoint Pharmaceuticals US, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
EyePoint Pharmaceuticals US, Inc.'s CMS-reported General Payments increased by $331.3K (+66.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: EYEPOINT US, INC.PY2023: EYEPOINT US, INC.PY2024: EyePoint Pharmaceuticals US, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $496,515.66
- PY2024
- $827,774.45
What the Data Shows for EyePoint Pharmaceuticals US, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For EyePoint Pharmaceuticals US, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 5 general-payment categories charted below, "Consulting Fee" is the largest at $695.2K across 192 transactions, 84.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 5 types of general payments, EyePoint Pharmaceuticals US, Inc.'s largest category was "Consulting Fee" at $695.2K - 84.0% of General Payments.
EyePoint Pharmaceuticals US, Inc. reports 5 general-payment categories - the top three are Consulting Fee (84.0%), Travel and Lodging (10.5%), and Food and Beverage (5.4%). The remaining 2 categories make up 0.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How EyePoint Pharmaceuticals US, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $695.2K | 192 | 84.0% |
| Travel and Lodging | $86.7K | 179 | 10.5% |
| Food and Beverage | $44.4K | 368 | 5.4% |
| Gift | $1.4K | 8 | 0.2% |
| Education | $39.98 | 1 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $413,264.22 (49.9%) of $827,774.45 in this company's General Payments records across 220 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for EyePoint Pharmaceuticals US, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Carl D Regillo
$117,237.23 across 13 reported transactions
- 2
CHARLES Clifton WYKOFF
$115,943.55 across 9 reported transactions
- 3
David S Boyer
$102,767.46 across 4 reported transactions
- 4
David Guyer
$59,438.59 across 2 reported transactions
- 5
DAVID Aarron EICHENBAUM
$17,877.39 across 18 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
EyePoint Pharmaceuticals US, Inc. ranks #181 of 1,925 by total payments (top 9% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,205 of 1,838 by HHI (bottom 34% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Expanding Innovations, Inc. : $130.8K total payments, HHI 649
- US Implant Solutions, LLC : $157.1K total payments, HHI 646
- Edap Technomed Inc : $640.3K total payments, HHI 644
- PENTAX of America, Inc. : $368.9K total payments, HHI 642
- Bone Support Inc. : $613.3K total payments, HHI 641
- Eagle Pharmaceuticals, Inc. : $177.1K total payments, HHI 640
- EyePoint Pharmaceuticals US, Inc. (this company) : $827.8K total payments, HHI 640
- Jenavalve Technology, Inc. : $869.0K total payments, HHI 640
- BioMarin Pharmaceutical Inc. : $3.0M total payments, HHI 639
- Roche Molecular Systems, Inc. : $3.5M total payments, HHI 638
- Aroa Biosurgery Incorporated : $591.0K total payments, HHI 637
- Napo Pharmaceuticals Inc : $189.6K total payments, HHI 636
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as EyePoint Pharmaceuticals US, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about EyePoint Pharmaceuticals US, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with EyePoint Pharmaceuticals US, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Dermavant Sciences, Inc.
$9.7M 73,486 recipients
Compare payment profiles
Supernus Pharmaceuticals, Inc.
$9.7M 61,253 recipients
Compare payment profiles
H. Lundbeck A S
$9.8M 303 recipients
Compare payment profiles
W. L. Gore & Associates, Inc.
$9.5M 25,860 recipients
Compare payment profiles
Applied Medical Research, Inc
$10.0M 0 recipients
Compare payment profiles
Put this to use
EyePoint Pharmaceuticals US, Inc. ranks #181 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where EyePoint Pharmaceuticals US, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just EyePoint Pharmaceuticals US, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.